Featured News
More News
SDRC investigators find evidence in CREDENCE clinical trial for efficacy and safety of canagliflozin for type2 diabetes
Sun Kim, MD, MS, associate professor of endocrinology, was a principal investigator at Stanford for a recent randomized, placebo-controlled clinical trial of the drug canagliflozin, which is a sodium glucose co-transporter 2 inhibitor.
Carolyn Bertozzi named Baker Family Director of Stanford ChEM-H
Chemistry Professor Carolyn Bertozzi has been named the Baker Family Director of Stanford ChEM-H, an interdisciplinary research institute launched in 2013 to bridge chemistry, engineering and medicine to improve human health.
Dr. Priya Prahalad discusses how easier-to-use technology helps young people with type 1 diabetes
Technology for treating type 1 diabetes is becoming easier to use, an especially beneficial change for teens and young adults, according to a recent study published in JAMA.
Uninterrupted access to continuous glucose monitors is required for improved health outcomes in publicly insured T1D children
Children with public health insurance may commonly face harmful insurance-related interruptions of continuous glucose monitoring that are not reversed when access is restored, according to a study published in Pediatric Diabetes.
Study led by SDRC investigator, Dr. Christopher Gardner, finds plant-based meat lowers some cardiovascular risk factors compared with red meat
A diet that includes an average of two servings of plant-based meat alternatives lowers some cardiovascular risk factors compared with a diet that instead includes the same amount of animal meat, Stanford Medicine scientists found.
A decade-long study finds that roughly 1 in 10 people carry genetic variants that may blunt the blood sugar-lowering effects of widely used diabetes medications — raising new questions about precision medicine in diabetes care. Read more...